Iodine

證據等級: L5

預測適應症: 0 個

Iodine: Repurposing Evaluation — Insufficient Evidence to Assess

One-Sentence Summary

Iodine (DrugBank ID: DB05382) is a halogen element with well-established clinical applications across antisepsis, thyroid disorders, and diagnostic imaging; however, the current Evidence Pack contains no registered indications, no TxGNN repurposing predictions, and no SAHPRA market authorisations, making a formal drug repurposing assessment impossible at this stage. Foundational data gaps — including mechanism of action and original indication text — must be resolved before this candidate can be meaningfully evaluated.

Quick Overview

Item	Content
Original Indication	Not established in current data
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 — no predictions generated
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing predictions were generated for this candidate. The Evidence Pack confirms that the predicted_indications array is empty, indicating that the drug either failed to match any knowledge graph node with sufficient predictive confidence, or that the upstream data gaps (missing original indications and MOA) prevented meaningful graph traversal.

Iodine as an element has broad and well-documented pharmacological applications — including topical antisepsis (povidone-iodine), thyroid ablation therapy (radioactive ¹³¹I), iodine deficiency supplementation, and use as a radiographic contrast component — but none of these indications were captured or formalised in the current data inputs. Without an anchoring indication in the knowledge graph, the TxGNN model cannot generate scored repurposing candidates.

Mechanistic bridging and indication-to-indication reasoning cannot be performed until original indication text and MOA data are retrieved from DrugBank (DB05382) and SAHPRA-approved product monographs. It should also be confirmed whether this DrugBank entry represents elemental iodine, a specific iodine salt, or radioactive iodine (¹³¹I), as each carries a fundamentally distinct pharmacological profile and would require separate evaluation.

South Africa Market Information

No SAHPRA-registered products were identified for Iodine (DB05382) in the current dataset. Market status is recorded as Not Marketed with 0 active licences.

Note: Iodine-containing compound products (e.g., povidone-iodine, potassium iodide, sodium iodide ¹³¹I) are registered under separate DrugBank identifiers and would need to be queried independently. If the clinical question relates to one of these compounds, the pipeline should be re-run against the appropriate DrugBank ID.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting platform.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Iodine (DB05382) contains no TxGNN repurposing predictions, no registered South African indications, and no retrievable safety profile. A structured repurposing evaluation cannot be conducted until the blocking data gaps identified below are resolved.

To proceed, the following is needed:

Clarify the drug entity: Confirm whether DB05382 refers to elemental iodine, a specific iodine compound (e.g., potassium iodide), or radioactive iodine (¹³¹I sodium iodide), as each requires an entirely different evaluation pathway
Retrieve original indications: Query the DrugBank API for DB05382 approved/experimental indications, and cross-reference with SAHPRA or TFDA product monographs if applicable
Retrieve mechanism of action (MOA): Query DrugBank API for pharmacodynamic and pharmacokinetic data for DB05382
Re-run the TxGNN pipeline: Once original indications and MOA are populated, re-run the KG and DL prediction modules to generate repurposing candidates with scored disease associations
Obtain safety data: Download and parse the approved Professional Information (PI) to extract warnings, contraindications, and drug–drug interactions
Assess compound-specific registrations: Search SAHPRA for related active substances (povidone-iodine, potassium iodide, sodium iodide ¹³¹I) under their respective DrugBank IDs to determine if any SA-registered formulations exist that could serve as a regulatory bridging pathway

⚠️ YMYL Disclaimer: This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Evidence gaps noted herein (DG001, DG002) are classified as Blocking and High severity respectively and must be resolved prior to any clinical or regulatory decision-making.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.